title: Helicobacter pylori therapy in children: overview and challenges.
abstract: Helicobacter pylori is one of the most common infections found in humans. It was first identified in 1982 and by 1989 had been associated with gastric inflammation and ulcers in adults and children. During the 1990's evidence emerged of its etiologic role in stomach cancers in adults. That the infection is common and may have serious consequences, has led to an avalanche of research during the last twenty years. During this time, there have been many studies on children which have sought an effective and safe treatment to eradicate the infection, but as yet, no therapy regimen has been found which is always effective and safe. This article provides information, from a pediatric point of view, on the major developments in the therapeutics and therapy of H. pylori infection. It examines first-line treatment regimens, evaluates the efficacy of the main drugs used in the management of (primary) H. pylori infection in children, assesses the potential for the use of probiotics and sequential therapy, examines therapeutic options after failure of initial treatment, and discusses factors affecting eradication rate, including antibiotic resistance, adherence to therapy, and bacterial factors.
authors.forename: C
authors.initials: C
authors.lastname: Chiesa
authors.forename: L
authors.initials: L
authors.lastname: Pacifico
authors.forename: C
authors.initials: C
authors.lastname: Anania
authors.forename: E
authors.initials: E
authors.lastname: Poggiogalle
authors.forename: F
authors.initials: F
authors.lastname: Chiarelli
authors.forename: J F
authors.initials: JF
authors.lastname: Osborn
mesh_terms: D002648:Child; D024881:Drug Resistance, Bacterial; D004359:Drug Therapy, Combination; D016481:Helicobacter Infections / Q000188:drug therapy*; D016480:Helicobacter pylori; D006801:Humans; D055118:Medication Adherence; D019936:Probiotics / Q000627:therapeutic use